RecruitingPhase 1Phase 2NCT06785636

Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617

A Phase 1b/2a, MultiCenter, Open- Label Study of Pocenbrodib as Monotherapy or in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Sponsor

Pathos AI, Inc.

Enrollment

252 participants

Start Date

Feb 7, 2025

Study Type

INTERVENTIONAL

Conditions

Prostate Cancer Neoplasms Neoplasms by Site mCRPC (Metastatic Castration-resistant Prostate Cancer)Urogenital Neoplasms Prostatic Neoplasms Prostatic Diseases Genital Neoplasms, Male Urogenital Cancers Male Urogenital Diseases

Summary

This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with Abiraterone acetate, Olaparib or 177Lu-PSMA-617 in patients with metastatic castration-resistant prostrate cancer (mCRPC).

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called pocenbrodib — alone or combined with other cancer therapies — for men with metastatic prostate cancer. It is an early-phase trial exploring safety, dosing, and early signs of effectiveness across different treatment combinations. **You may be eligible if...** - You are 18 or older - You have been diagnosed with metastatic prostate cancer confirmed by biopsy - Your cancer has been confirmed with imaging - You meet the specific requirements for one of the drug combination groups **You may NOT be eligible if...** - Your most recent biopsy shows small cell or neuroendocrine prostate cancer - You have liver metastases (cancer spread to the liver) - You have recently taken other cancer drugs like enzalutamide, apalutamide, or darolutamide - You have certain other health conditions that make combination treatment unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPocenbrodib

Pocenbrodib is a selective oral inhibitor of CBP/p300 bromodomain interaction with acetylated lysines on histones.

DRUGCohort 2A (Pocenbrodib monotherapy), Cohort 2B (Pocenbrodib + abiraterone acetate), Cohort 2C (Pocenbrodib + olaparib), Cohort 2D (Pocenbrodib + 177Lu-PSMA-617

Pocenbrodib alone or in combination

Locations(18)

MemorialCare Orange Coast Medical Center

Fountain Valley, California, United States

Cancer and Blood Research Center

Los Alamitos, California, United States

University of Colorado Health

Aurora, Colorado, United States

Mount Sinai Medical Center

Miami, Florida, United States

Emory University Hospital

Atlanta, Georgia, United States

University of Chicago

Chicago, Illinois, United States

Community Health Network

Indianapolis, Indiana, United States

Ochsner

Jefferson, Louisiana, United States

Johns Hopkins Hospital

Baltimore, Maryland, United States

Karmanos Cancer Institute

Detroit, Michigan, United States

Siteman Cancer Center

St Louis, Missouri, United States

Nebraska Cancer Specialists

Omaha, Nebraska, United States

Duke University medical center

Durham, North Carolina, United States

The Ohio State University

Columbus, Ohio, United States

Taylor Cancer Research Center

Maumee, Ohio, United States

University of Texas Southwestern Medical Center

Dallas, Texas, United States

Oncology Consultants, P.A

Houston, Texas, United States

NEXT Oncology - Virginia

Fairfax, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06785636

Related Trials

Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System

NCT068073593 locations

Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer

NCT046926751 location

DESTINY-PANTUMOUR04

NCT0712400017 locations

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

NCT0700515433 locations

Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members

NCT000710451 location